Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Coronary heart disease (CHD) poses a significant global health burden.
• Cholesterol levels are a known risk factor for major coronary events.
• Statins, like simvastatin, are widely used to manage hyperlipidemia and reduce cardiovascular risk.

Purpose of the Study:

• To investigate the relationship between baseline cholesterol levels and the risk of major coronary events in CHD patients.
• To evaluate the efficacy of simvastatin therapy in reducing major coronary events across different baseline lipid profiles.

Main Methods:

• Analysis of data from the Scandinavian Simvastatin Survival Study (4S).
• Randomized controlled trial comparing placebo with simvastatin therapy in CHD patients.
• Stratification of patients into quartiles based on baseline total, HDL, and LDL cholesterol levels.

Main Results:

• Simvastatin significantly reduced the risk of major coronary events (coronary death, non-fatal myocardial infarction) in all patient quartiles.
• Relative risk reduction was consistent across all quartiles of baseline low-density-lipoprotein cholesterol (35% lowest, 36% highest).
• Similar risk reductions were observed across quartiles for total and high-density-lipoprotein cholesterol.

Conclusions:

• Simvastatin therapy provides significant and consistent risk reduction for major coronary events in patients with coronary heart disease.
• The benefit of simvastatin in reducing cardiovascular events is not dependent on the baseline level of LDL cholesterol.
• These findings support the use of simvastatin for secondary prevention in patients with established coronary heart disease.